Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea
Background/Purpose(s): The World Health Organization (WHO) released treatment guidelines for multidrug resistant tuberculosis (MDR-TB) in 2008, with subsequent revisions in 2011; Korea disseminated corresponding guidelines in 2011 and 2014, respectively. Thus, we aimed to investigate the temporal tr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S168411822100267X |
| _version_ | 1811341193076801536 |
|---|---|
| author | Han Eol Jeong Junyeong Choi In-Sun Oh Hyunjin Son Seung Hun Jang Sun-Young Jung Ju-Young Shin |
| author_facet | Han Eol Jeong Junyeong Choi In-Sun Oh Hyunjin Son Seung Hun Jang Sun-Young Jung Ju-Young Shin |
| author_sort | Han Eol Jeong |
| collection | DOAJ |
| description | Background/Purpose(s): The World Health Organization (WHO) released treatment guidelines for multidrug resistant tuberculosis (MDR-TB) in 2008, with subsequent revisions in 2011; Korea disseminated corresponding guidelines in 2011 and 2014, respectively. Thus, we aimed to investigate the temporal trends of and the updated guideline's impact on the prescription patterns of anti-TB drugs. Methods: We conducted a time-series study using Korea's nationwide healthcare database (2007–2015), where patients with TB or MDR-TB were included. Only anti-TB drugs prescribed during the intensive phase of treatment for TB (two months) or MDR-TB (eight months) were assessed. We estimated the annual utilization of TB treatment regimens and the relative difference (RD) in the proportion of MDR-TB treatment medications between the following periods: before the first Korean guideline (June 2008 to March 2011); between the first and revised guidelines (April 2011 to July 2014); after the revised guideline (August 2014 to December 2015). Results: Of 3523 TB (mean age 54.1 years; male 56.8%) patients, treatment regimens for TB complied with guideline recommendations as >80% of patients received either quadruple (mean 66.8%) or triple (14.5%) therapy of first-line anti-TB drugs. Following the WHO's guideline update, prescription patterns changed accordingly among 111 MDR-TB (mean age 46.0 years; male 67.6%) patients, as use of pyrazinamide (RD +20.3%) and prothionamide (+11.5%) increased (recommended to be compulsory), and streptomycin (−43.1%) decreased (ototoxicity risks). Conclusions: Anti-TB drug prescription patterns for both TB and MDR-TB well reflected WHO's treatment guideline as well as corresponding domestic guidelines of South Korea. |
| first_indexed | 2024-04-13T18:53:07Z |
| format | Article |
| id | doaj.art-cfbfe1f925fc47fc8fd76ccbe1fad344 |
| institution | Directory Open Access Journal |
| issn | 1684-1182 |
| language | English |
| last_indexed | 2024-04-13T18:53:07Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Microbiology, Immunology and Infection |
| spelling | doaj.art-cfbfe1f925fc47fc8fd76ccbe1fad3442022-12-22T02:34:21ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822022-10-01555917925Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South KoreaHan Eol Jeong0Junyeong Choi1In-Sun Oh2Hyunjin Son3Seung Hun Jang4Sun-Young Jung5Ju-Young Shin6School of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea; Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon 16149, South KoreaSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, South KoreaSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, South Korea; Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon 16149, South KoreaDepartment of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, South KoreaDivision of Pulmonary, Allergy, and Critical Care Medicine, College of Medicine, Hallym University Sacred Heart Hospital, Hallym University, Anyang 14068, South KoreaCollege of Pharmacy, Chung-Ang University, Seoul 06974, South KoreaDepartment of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul 06355, South Korea; Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon 16149, South Korea; Corresponding author. School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, South Korea.Background/Purpose(s): The World Health Organization (WHO) released treatment guidelines for multidrug resistant tuberculosis (MDR-TB) in 2008, with subsequent revisions in 2011; Korea disseminated corresponding guidelines in 2011 and 2014, respectively. Thus, we aimed to investigate the temporal trends of and the updated guideline's impact on the prescription patterns of anti-TB drugs. Methods: We conducted a time-series study using Korea's nationwide healthcare database (2007–2015), where patients with TB or MDR-TB were included. Only anti-TB drugs prescribed during the intensive phase of treatment for TB (two months) or MDR-TB (eight months) were assessed. We estimated the annual utilization of TB treatment regimens and the relative difference (RD) in the proportion of MDR-TB treatment medications between the following periods: before the first Korean guideline (June 2008 to March 2011); between the first and revised guidelines (April 2011 to July 2014); after the revised guideline (August 2014 to December 2015). Results: Of 3523 TB (mean age 54.1 years; male 56.8%) patients, treatment regimens for TB complied with guideline recommendations as >80% of patients received either quadruple (mean 66.8%) or triple (14.5%) therapy of first-line anti-TB drugs. Following the WHO's guideline update, prescription patterns changed accordingly among 111 MDR-TB (mean age 46.0 years; male 67.6%) patients, as use of pyrazinamide (RD +20.3%) and prothionamide (+11.5%) increased (recommended to be compulsory), and streptomycin (−43.1%) decreased (ototoxicity risks). Conclusions: Anti-TB drug prescription patterns for both TB and MDR-TB well reflected WHO's treatment guideline as well as corresponding domestic guidelines of South Korea.http://www.sciencedirect.com/science/article/pii/S168411822100267XMultidrug resistant tuberculosisNationwide studyPrescription patternsTime seriesTuberculosis |
| spellingShingle | Han Eol Jeong Junyeong Choi In-Sun Oh Hyunjin Son Seung Hun Jang Sun-Young Jung Ju-Young Shin Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea Journal of Microbiology, Immunology and Infection Multidrug resistant tuberculosis Nationwide study Prescription patterns Time series Tuberculosis |
| title | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea |
| title_full | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea |
| title_fullStr | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea |
| title_full_unstemmed | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea |
| title_short | Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea |
| title_sort | temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in south korea |
| topic | Multidrug resistant tuberculosis Nationwide study Prescription patterns Time series Tuberculosis |
| url | http://www.sciencedirect.com/science/article/pii/S168411822100267X |
| work_keys_str_mv | AT haneoljeong temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT junyeongchoi temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT insunoh temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT hyunjinson temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT seunghunjang temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT sunyoungjung temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea AT juyoungshin temporaltrendsofpharmacologictreatmentsfortuberculosisandmultidrugresistanttuberculosisfollowingdisseminationoftreatmentguidelinesinsouthkorea |